YPHA Panoramica delle azioni Astellas Pharma Inc. produce, commercializza, importa ed esporta prodotti farmaceutici in Giappone e a livello internazionale. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Astellas Pharma Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Astellas Pharma Prezzi storici delle azioni Prezzo attuale dell'azione JP¥9.10 Massimo di 52 settimane JP¥11.20 Minimo di 52 settimane JP¥8.40 Beta 0.23 Variazione di 1 mese 1.11% Variazione a 3 mesi -12.50% Variazione di 1 anno -11.65% Variazione a 3 anni -37.67% Variazione a 5 anni n/a Variazione dall'IPO -38.10%
Notizie e aggiornamenti recenti Astellas Receives Health Canada Approval for Vyloy® (Zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
Astellas Pharma Inc. Announces China's National Medical Products Administration (Nmpa) Approves Padcev™ in Combination with Keytruda® (Pembrolizumab) for the Treatment of Advanced Bladder Cancer Jan 08
China's National Medical Products Administration Approves Vyloy (Zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Jan 06
Astellas Pharma Inc. to Report Q3, 2025 Results on Feb 04, 2025 Jan 03
Astellas Pharma Inc. Vyloy™ (Zolbetuximab-Clzb) Approved by U.S. Fda for Treatment of Advanced Gastric and Gej Cancer Oct 19
Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024 Oct 05 Vedi altri aggiornamenti Astellas Receives Health Canada Approval for Vyloy® (Zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
Astellas Pharma Inc. Announces China's National Medical Products Administration (Nmpa) Approves Padcev™ in Combination with Keytruda® (Pembrolizumab) for the Treatment of Advanced Bladder Cancer Jan 08
China's National Medical Products Administration Approves Vyloy (Zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Jan 06
Astellas Pharma Inc. to Report Q3, 2025 Results on Feb 04, 2025 Jan 03
Astellas Pharma Inc. Vyloy™ (Zolbetuximab-Clzb) Approved by U.S. Fda for Treatment of Advanced Gastric and Gej Cancer Oct 19
Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024 Oct 05
Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024 Oct 04
Astellas Pharma Inc. Receives Approval from the European Commission for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer Sep 24
Astellas Pharma Inc. to Present VEOZAH (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society Sep 04
European Commission Approves Astellas Pharma Inc.'s PADCEV in Combination with KEYTRUDA (Pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer Aug 28
Astellas Pharma Inc. Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy Aug 27
Astellas Pharma Inc. Announces Center for Drug Evaluation of China's National Medical Products Administration Approves Padcev (Enfortumab Vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer Aug 20 Astellas Pharma Inc. Receives Positive Chmp Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer
Astellas Pharma Inc. to Report Q1, 2025 Results on Aug 01, 2024 Jun 29 U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.’ Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date May 31
Astellas Pharma Inc., Annual General Meeting, Jun 20, 2024
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting Apr 25 Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024
Astellas Pharma Inc. to Report Fiscal Year 2024 Results on Apr 25, 2024 Apr 03
U.S. FDA Accepts Astellas’ Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy Apr 02
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer Mar 28
Astellas Pharma Inc.'s Vyloy™? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer Mar 27
Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting Mar 22
Astellas Pharma Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan Mar 05
Astellas Pharma Inc. Announces Japan's Ministry of Health, Labour and Welfare Grants Priority Review for the Company's Supplemental New Drug Application (sNDA) for PADCEV with KEYTRUDA Feb 16
Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer Jan 31 European Medicines Agency Validates Type II Variation Application for PADCEV®? (enfortumab Vedotin) with KEYTRUDA®? (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer Jan 27
Astellas Pharma Inc. Provides Update on Zolbetuximab Biologics License Application in U.S Jan 09
Astellas Pharma Inc. to Report Q3, 2024 Results on Feb 05, 2024 Dec 28
Astellas Pharma Inc. Announces EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children Dec 18 Pfizer Inc. and Astellas Pharma Inc. Announce U.S. Food and Drug Administration Approved PADCEV (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC]) with KEYTRUDA (pembrolizumab, a PD-1 inhibitor) for the Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer (la/mUC) Dec 16
Astellas Pharma Inc. Announces That Its VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause Dec 11
Astellas Pharma US, Inc. Announces FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis Dec 09 Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer Dec 02
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy Nov 30 Pfizer and Astellas' Xtandi Approve by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Seagen Inc. and Astellas Pharma Inc. Announces Results from the Phase 3 EV-302 Clinical Trial for PADCEV (Enfortumab Vedotin-Ejfv) in Combination with Keytruda (Pembrolizumab) Versus Chemotherapy Oct 24
Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023 Oct 16
Astellas Receives Positive Chmp Opinion for Veoza (Fezolinetant) Oct 14
Astellas Pharma Inc. to Report Q2, 2024 Results on Nov 01, 2023 Sep 28
Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial Sep 23 Astellas Pharma Inc. Announces China's National Medical Products Administration Accepts New Drug Application for Xtandi®? (Enzalutamide) in Metastatic Hormone-S Sensitive Prostate Cancer
Astellas Pharma Inc. Announces Positive 24-Month Topline Results from the Phase 3 GATHER2 Clinical Trial Evaluating the Efficacy and Safety of IZERVAY Sep 19
European Medicines Agency Validates Type II Variation for Astellas' XTANDI (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence Sep 13
Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503). Aug 30
Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503). Aug 29 FDA Grants Priority Review for XTANDI in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence Aug 24
Astellas Pharma Inc. Announces European Medicines Agency Accepts for Regulatory Review the Marketing Authorization Application for Avacincaptad Pegol Aug 18
U.S. FDA Accepts Astellas Pharma US, Inc.'s sNDA for CRESEMBA® (isavuconazonium sulfate) in Children Aug 11
Astellas Pharma Inc. Announces the U.S. Food and Drug Administration Approves Izervay (Avacincaptad Pegol Intravitreal Solution) for the Treatment of Geographic At the 12-Month Primary Endpoint Across Two Phase 3 Clinical Trials Aug 09 Astellas Pharma Inc. Revises Consolidated Earnings Guidance on Full Basis for the Full-Year 2023 Aug 03
China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab Aug 01
European Medicines Agency Accepts Astellas' Marketing Authorization Application for Zolbetuximab Jul 14 Astellas Pharma Inc. to Report Q1, 2024 Results on Aug 01, 2023 Jul 12
Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application Jul 06
Astellas Pharma Inc. Announces Positive Topline Results from the Phase 3b DayLIGHT Clinical Trial for Fezolinetant Jun 28
Astellas Pharma Inc. Confirms Unfavorable District Court Decision in Myrbetriq U.S. Patent Trial Jun 12
Astellas Pharma Inc. Announces Submission of New Drug Application to Japan's Ministry of Health, Labour and Welfare for Zolbetuximab Jun 09
Astellas' Veozah Tm (Fezolinetant) Approved by U.S. Fda for Treatment of Vasomotor Symptoms Due to Menopause May 17 Astellas Pharma Inc. Provides Update on Fezolinetant New Drug Application in U.S Feb 20
Astellas Pharma Inc. Reaffirms Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023 Astellas Pharma Inc. Announces CEO Changes, Effective April 1, 2023
Sandoz AG agreed to acquire Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503). Jan 25
Sandoz AG agreed to acquire Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503). Jan 24
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease Jan 21
Astellas Pharma Inc. Presents Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers Symposium Jan 20
Astellas Pharma Inc. Receives SBTi Approval for Revised Science-Based Climate Goals to Reduce Greenhouse Gas Emissions Jan 19
Astellas Pharma Inc. to Report Q3, 2023 Results on Feb 06, 2023 Dec 29 Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer Dec 21
Rendimenti per gli azionisti YPHA DE Pharmaceuticals DE Mercato 7D 2.2% 1.5% 1.9% 1Y -11.7% -7.6% 15.1%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: YPHA ha avuto una performance inferiore rispetto al German Pharmaceuticals che ha registrato un rendimento -7.6 % nell'ultimo anno.
Rendimento vs Mercato: YPHA ha avuto una performance inferiore al mercato German che ha registrato un rendimento 15.1 % nell'ultimo anno.
Volatilità dei prezzi Is YPHA's price volatile compared to industry and market? YPHA volatility YPHA Average Weekly Movement 3.2% Pharmaceuticals Industry Average Movement 5.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Prezzo delle azioni stabile: YPHA non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato German.
Volatilità nel tempo: La volatilità settimanale ( 3% ) di YPHA è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1923 14,754 Naoki Okamura www.astellas.com
Astellas Pharma Inc. produce, commercializza e importa ed esporta prodotti farmaceutici in Giappone e a livello internazionale. L'azienda fornisce XTANDI, un trattamento per il cancro alla prostata; XOSPATA, un trattamento per i pazienti affetti da leucemia mieloide acuta recidivata o refrattaria con mutazione FLT3; e PADCEV, un trattamento per i pazienti affetti da cancro uroteliale metastatico. L'azienda offre anche Evrenzo, un trattamento per l'anemia associata alla malattia renale cronica; Betanis/Myrabetriq/BETMIGA, un trattamento per la vescica iperattiva; e gli immunosoppressori Prograf e Advagraf/Graceptor/ASTAGRAF XL.
Mostra di più Astellas Pharma Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Astellas Pharma con la sua capitalizzazione di mercato? YPHA statistiche fondamentali Capitalizzazione di mercato €16.86b Guadagni(TTM ) €340.55m Ricavi(TTM ) €11.02b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) YPHA Conto economico (TTM ) Ricavi JP¥1.77t Costo del fatturato JP¥322.95b Profitto lordo JP¥1.45t Altre spese JP¥1.39t Guadagni JP¥54.75b
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
Feb 04, 2025
Utile per azione (EPS) 30.58 Margine lordo 81.78% Margine di profitto netto 3.09% Rapporto debito/patrimonio netto 61.2%
Come si è comportato YPHA nel lungo periodo?
Vedi performance storica e confronto Dividendi
4.9% Rendimento attuale del dividendo
350% Rapporto di remunerazione
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/31 10:38 Prezzo dell'azione a fine giornata 2025/01/31 00:00 Guadagni 2024/09/30 Guadagni annuali 2024/03/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Astellas Pharma Inc. è coperta da 30 analisti. 15 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Atsushi Seki Barclays Koichi Mamegano BofA Global Research Hazim Bahari CFRA Equity Research
Mostra 27 altri analisti 
